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Abstract
Mast cell activation disease comprises disorders characterized by accumulation of genetically altered mast cells
and/or abnormal release of these cells’ mediators, affecting functions in potentially every organ system, often
without causing abnormalities in routine laboratory or radiologic testing. In most cases of mast cell activation
disease, diagnosis is possible by relatively non-invasive investigation. Effective therapy often consists simply of
antihistamines and mast cell membrane-stabilising compounds supplemented with medications targeted at
specific symptoms and complications. Mast cell activation disease is now appreciated to likely be considerably
prevalent and thus should be considered routinely in the differential diagnosis of patients with chronic multisystem
polymorbidity or patients in whom a definitively diagnosed major illness does not well account for the entirety of
the patient’s presentation.
Introduction
The term mast cell activation disease (MCAD) denotes
a collection of disorders characterized by (1) accumula-
tion of pathological mast cells in potentially any or all
organs and tissues and/or (2) aberrant release of variable
subsets of mast cell mediators. A classification has been
proposed which differentiates several types and sub-
classes of MCAD (Table 1). The traditionally recognized
subclass termed systemic mastocytosis (SM) includes dis-
orders characterized by certain pathological immunohis-
tochemical and mutational findings (the WHO criteria;
Table 2; [1,2]) which are divided into several subtypes
(Table 1). On the other hand, mast cell activation syn-
drome (MCAS) presents a complex clinical picture of
multiple mast cell mediator-induced symptoms, failure
to meet the WHO criteria for diagnosis of SM, and
exclusion of relevant differential diagnoses [1,3-5].
Symptoms observed in patients with MCAS are little, if
any, different from those seen in patients with SM [6-8].
Patients present variable and often fluctuating patterns
of symptoms (Table 3; [9-15]) which depend on the
tissue responses to mast cell mediators released both
spontaneously and in response to trigger stimuli.
A rare variant of MCAD is mast cell leukemia (MCL;
Table 1). This aggressive mast cell neoplasm is defined
by increased numbers of mast cells in bone marrow
smears (≥20%) and by circulating mast cells (reviewed in
[2]). Patients typically suffer from rapidly progressive
organopathy involving the liver, bone marrow and other
organs. The bone marrow typically shows a diffuse,
dense infiltration with mast cells. In typical MCL, mast
cells account for more than 10% of blood leukocytes. In
a smaller group of patients, pancytopenia occurs and
mast cells account for less than 10% (aleukemic variant
of MCL). The prognosis in MCL is poor. Most patients
survive less than 1 year and respond poorly to cytore-
ductive drugs or chemotherapy.
Mast cell activation disease in general has long been
thought to be rare. However, although SM and MCL as
defined by the WHO criteria are truly rare, recent find-
ings suggest MCAS is a fairly common disorder. Evi-
dence has been presented for a causal involvement of
pathologically active mast cells not only in the patho-
genesis of SM and MCAS but also in the etiology of
idiopathic anaphylaxis [16-18], interstitial cystitis [19],
some subsets of fibromyalgia [20,21] and some subsets
of irritable bowel syndrome [22-24].
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Pathogenesis
Mutations in kinases (particularly in the tyrosine kinase
Kit) and in enzymes and receptors (JAK2, PDGFRa,
RASGRP4, Src-kinases, c-Cbl-encoded E3 ligase, hista-
mine H4 receptor) which are crucially involved in the
regulation of mast cell activity have been identified as
necessary to establish a clonal mast cell population, but
other abnormalities yet to be determined must be added
for the development of a clinically symptomatic disease
([7,8,25,26]; further references therein). The observations
that the same KIT mutation (e.g. D816V) can be asso-
ciated with both good prognosis as well as progression
to advanced disease [27] and that the D816V mutation
has also been detected in healthy subjects [28] highlight
the potential role of other factors in determining the
progression/outcome of the disease. Recent findings sug-
gest that the immunohistochemical and morphological
alterations which constitute the WHO criteria for SM
(formation of mast cell clusters; spindle-shaped mor-
phology of mast cells; expression of CD25 on mast cells;
Table 2) are causally related to and specific for the
occurrence of a mutation in codon 816 of tyrosine
kinase Kit in the affected mast cells [6,29-31]. Another
aspect that limits the diagnostic value of this mutation
is that during progression of SM the Kit mutant D816V
may disappear ([32]; own unpublished observation).
Taken together, the recent genetic findings suggest that
the clinically different subtypes of MCAD (encompass-
ing SM, MCL, and MCAS) should be more accurately
regarded as varying presentations of a common generic
root process of mast cell dysfunction than as distinct
diseases [4,7,8,11].
Clinical diagnostics
MCAD is first suspected on clinical grounds, based on
recognition of compatible mast cell mediator-related
symptoms and, in some, identification of typical skin
lesions. The clinical presentation of MCAD is very
diverse, since due to both the widespread distribution of
mast cells and the great heterogeneity of aberrant med-
iator expression patterns, symptoms can occur in vir-
tually all organs and tissues (Table 3). Moreover,
symptoms often occur in a temporally staggered fashion,
waxing and waning over years to decades. Symptoms
often initially manifest during adolescence or even child-
hood or infancy but are recognized only in retrospect as
MCAD-related. Clinical features and courses vary
greatly and range from very indolent with normal life
expectancy to highly aggressive with reduced survival
times. Physical examination should include inspection
for a large assortment of types of skin lesions, testing
Table 1 Classification of mast cell activation disease
(modified from [2-4])
Mast cell activation disease
(MCAD)
Mast cell activation syndrome
(MCAS)
Systemic mastocytosis (SM)
defined by the WHO criteria • Indolent systemic mastocytosis
• Isolated bone marrow mastocytosis
• Smoldering systemic mastocytosis
• Systemic mastocytosis with an
associated clonal hematologic non-
mast cell lineage disease
• Aggressive systemic mastocytosis
Mast cell leukemia (MCL)
Table 2 Criteria proposed to define mast cell activation
disease (for references, see text)
Criteria to define mast cell
activation syndrome
WHO criteria to define systemic
mastocytosis
Major criteria Major criterion
1. Multifocal or disseminated
dense infiltrates of mast cells in
bone marrow biopsies and/or in
sections of other extracutaneous
organ(s) (e.g., gastrointestinal tract
biopsies; CD117-, tryptase- and
CD25-stained)
Multifocal dense infiltrates of mast
cells (>15 mast cells in aggregates)
in bone marrow biopsies and/or in
sections of other extracutaneous
organ(s) (CD117-, tryptase- and
CD25-stained)
2. Unique constellation of clinical
complaints as a result of a
pathologically increased mast cell
activity (mast cell mediator release
syndrome)
Minor criteria Minor criteria
1. Mast cells in bone marrow or
other extracutaneous organ(s)
show an abnormal morphology
(>25%) in bone marrow smears or
in histologies
1. Mast cells in bone marrow or
other extracutaneous organ(s)
show an abnormal morphology
(>25%) in bone marrow smears or
in histologies
2. Mast cells in bone marrow
express CD2 and/or CD25
2. Mast cells in bone marrow
express CD2 and/or CD25
3. Detection of genetic changes in
mast cells from blood, bone
marrow or extracutaneous organs
for which an impact on the state
of activity of affected mast cells in
terms of an increased activity has
been proved.
3. c-kit mutation in tyrosine kinase
at codon 816 in mast cells in
extracutaneous organ(s)
4. Evidence of a pathologically
increased release of mast cell
mediators by determination of the
content of
4. Serum total tryptase >20 ng/ml
(does not apply in patients who
have associated hematologic non-
mast-cell lineage disease)
• tryptase in blood
• N-methylhistamine in urine
• heparin in blood
• chromogranin A in blood
• other mast cell-specific
mediators (e.g., leukotrienes,
prostaglandin D2)
The diagnosis mast cell activation syndrome is made if both major criteria or
the second criterion and at least one minor criterion are fulfilled. According to
the WHO criteria [1], the diagnosis systemic mastocytosis is established if the
major criterion and at least one minor criterion or at least three minor criteria
are fulfilled.
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for dermatographism (Darier’s sign), and palpating for
hepatosplenomegaly and lymphadenopathy. A diagnostic
algorithm is shown in Figure 1. Recognition of a mast
cell mediator release syndrome, i.e. a pattern of symp-
toms caused by the unregulated increased release of
mediators from mast cells, can be aided by use of a vali-
dated checklist [2,11,12,33] which lists the complaint
complexes to be considered. In addition to the detection
of the characteristic clinical constellation of findings, it
must be investigated whether levels of the mast cell-spe-
cific mediators tryptase, histamine, and heparin are ele-
vated in the blood, whether the excretion of the
histamine metabolite methylhistamine into the urine is
increased, and whether mast cell activity-related eosino-
philia, basophilia or monocytosis in the blood can be
observed. Other useful markers fairly specific to mast
cells include serum chromogranin A (in the absence of
cardiac and renal failure, neuroendocrine cancer, and
proton pump inhibitor use) and serum and urinary leu-
kotriene and prostaglandin isoforms (e.g., leukotriene E4,
prostaglandin D2, and prostaglandin 9a,11bPGF2).
Together with a characteristic clinical presentation,
abnormal markers can be of diagnostic, therapeutic and
prognostic relevance. However, it remains unsettled
whether demonstration of an elevation of mast cell
activity markers is absolutely necessary for diagnosis of
MCAD because (1) many conditions (e.g., degrading
enzymes, complexing molecules, tissue pH) may attenu-
ate or impede spill-over of exocytosed mediators from
tissues into the blood, (2) only a handful of the more
than 60 releasable mast cell mediators can be detected
by routine commercial techniques, and (3) mediator
release syndrome may be due to an amplification cas-
cade of basophil, eosinophil, and general leukocyte acti-
vation induced by liberation of only a few mast cell
mediators [34] which, again, may not be detectable by
present techniques.
When relevant differential diagnoses of a mast cell
activation disease (Table 4) which may present mast cell
mediator-induced symptoms by activation of normal
mast cells (e.g., allergy) or as result of non-mast-cell-
specific expression of mediators (e.g., neuroendocrine
cancer) are excluded, the cause of the mast cell media-
tor release syndrome must lie in the uncontrolled
increase in activity of pathologically altered mast cells.
Patients with most types of MCAD often initially enjoy
symptom-free intervals interspersed amongst sympto-
matic periods. Over time, symptom-free intervals
shorten, and finally symptoms become chronic with
intensity which fluctuates but with an overall trend
toward steadily increasing intensity. Following the pro-
posed revised diagnostic criteria (Table 2; [3-5,9,35]),
MCAD is diagnosed if either both major criteria or one
major criterion and at least one minor criterion are met.
After clinical diagnosis, a bone marrow biopsy is usually
recommended because based on current information it
cannot be predicted whether the genetic alterations
inducing pathological mast cell activity in affected mast
cells have not also induced disturbances in hematopoie-
tic non-mast cell lineages. SM due to codon 816 muta-
tions has been shown to be associated with myeloid
neoplasms (and, less frequently, with B-cell neoplasms)
frequently enough to warrant routine marrow biopsy
when SM is suspected (e.g., serum tryptase elevation per
the WHO criteria, frequent unprovoked anaphylactoid
events). The frequency of discovery of associated hema-
tologic neoplasms on marrow biopsy at the time of diag-
nosis of MCAS remains unclear but in our experience
appears very low. However, a byproduct of marrow
biopsy is that immunohistochemical analysis of the spe-
cimen may permit the classification of the mast cell acti-
vation disease as SM defined by the WHO criteria or as
MCAS (Table 2). In this context, it has to be considered
that due to the typically patchy distribution of mast cell
Table 3 Frequent signs and clinical symptoms ascribed to
episodic unregulated release of mast cell mediators
(modified from [12]; further references therein; an
exhaustive survey is given in [50])
Signs and
Symptoms
Abdominal abdominal pain, intestinal cramping and bloating,
diarrhea and/or obstipation, nausea, non-cardiac
chest pain, Helicobacter pylori-negative gastritis,
malabsorption
Oropharyngeal burning pain, aphthae
Respiratory cough, asthma-like symptoms, dyspnea, rhinitis,
sinusitis
Ophthalmologic conjunctivitis, difficulty in focusing
Hepatic splenomegaly, hyperbilirubinemia, elevation of liver
transaminases, hypercholesterolemia
Splenomegaly
Lymphadenopathy
Cardiovascular tachycardia, blood pressure irregularity
(hypotension and/or hypertension), syncope, hot
flush
Neuropsychiatric headache, neuropathic pain, polyneuropathy,
decreased attention span, difficulty in
concentration, forgetfulness, anxiety, sleeplessness,
organic brain syndrome, vertigo, lightheadedness,
tinnitus
Cutaneous urticaria pigmentosa, hives, efflorescences with/
without pruritus, telangiectasia, flushing,
angioedema
Abnormal
bleeding
Musculoskeletal muscle pain, osteoporosis/osteopenia, bone pain,
migratory arthritis
Interstitial cystitis
Constitutional fatigue, asthenia, fever, environmental sensitivities
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Table 4 Diseases which should be considered as differential diagnoses of mast cell activation disease, since they may
mimick or may be associated with mast cell activation (diagnostic procedure of choice in parentheses)
Endocrinologic disorders Diabetes mellitus (laboratory determination)
Pancreatic endocrine tumours (gastrinoma, insulinoma, glucagonoma, somatostatinoma, VIPoma; laboratory
determination, medical history)
Porphyria (laboratory determination)
Disorders of the thyroid gland (laboratory determination)
Morbus Fabry (clinical picture, molecular genetic investigation)
Gastrointestinal disorders Helicobacter-positive gastritis (gastroscopy, biopsy)
Infectious enteritis (stool examination)
Eosinophilic gastroenteritis (endoscopy, biopsy)
Parasitic infections (stool examination)
Inflammatory bowel disease (endoscopy, biopsy)
Celiac disease (endoscopy, biopsy, laboratory determination)
Primary lactose intolerance (molecular genetic investigation)
Microscopic colitis (endoscopy, biopsy)
Amyloidosis (endoscopy, biopsy)
Intestinal obstructions by adhesions, volvulus and other reasons (medical history, imaging methods, laparoscopy)
Hepatitis (laboratory determination)
Cholelithiasis (imaging methods)
Hereditary hyperbilirubinemia (laboratory determination)
Immunological/neoplastic
diseases
Carcinoid tumour (medical history, laboratory determination)
Pheochromocytoma (medical history, laboratory determination)
Primary gastrointestinal allergy (medical history)
Hypereosinophilic syndrome (laboratory determination)
Hereditary angioedema (medical history, laboratory determination)
Vasculitis (medical history, laboratory determination)
Intestinal lymphoma (imaging methods)
Figure 1 Diagnostic algorithm.
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infiltration in the bones a single marrow biopsy fails to
find systemic mastocytosis in the marrow approximately
one-sixth of the time [36].
An aggressive course of MCAD is characterized and
defined by organopathy caused by pathologic infiltration
of various organs by neoplastic mast cells inducing an
impairment of organ function. Organopathy due to mast
cell infiltration is indicated by findings termed C-find-
ings: (1) significant cytopenia(s); (2) hepatomegaly with
impairment of liver function due to mast cell infiltra-
tion, often with ascites; (3) splenomegaly with hypers-
plenism; (4) malabsorption with hypoalbuminemia and
weight loss; (5) life-threatening impairment of organ
function in other organ systems; (6) osteolyses and/or
severe osteoporosis with pathologic fractures. Urticaria
pigmentosa-like skin lesions are usually absent. In con-
trast to MCL, the bone marrow smear shows fewer than
20% mast cells (reviewed in [2]). Mast cell infiltration
with organomegaly but without end organ dysfunction
(hepatomegaly, splenomegaly, lymphadenopathy, bone
marrow alterations) is a B-finding and may occur in a
subvariant of SM (smoldering SM) with high mast cell
burden.
Treatment of mast cell activation diseases
The cornerstone of therapy is avoidance of identifiable
triggers for mast cell degranulation such as animal
venoms, extremes of temperature, mechanical irritation,
alcohol, or medications (e.g., aspirin, radiocontrast
agents, certain anesthetic agents). Individual patients
may have variable tolerance patterns and avoidance lists,
but it also is not uncommon to have no identifiable,
reliable triggers.
Drug treatment of MCAD patients is highly individua-
lized. Curative therapies are not avail-able, and each
MCAD patient should be treated in accordance with his
symptoms and complications. Irrespective of the specific
clinical presentation of MCAD, evidence-based therapy
consists of trigger avoidance, antihistamines, and mast
cell membrane-stabilising compounds (basic therapy,
Table 5) supplemented as needed by medications target-
ing individual mast cell mediator-induced symptoms or
complications (symptomatic therapy, Table 5). First hints
of success with any given therapy are usually seen within
4 weeks once suitable dosing has been achieved Multiple
simultaneous changes in the medication regimen are dis-
couraged since such can confound identification of the
Table 5 Treatment options for mast cell activation disease
Basic therapy (continuous oral combination
therapy to reduce mast cell activity)
• H1-histamine receptor antagonist (to block activating H1-histamine receptors on mast cells; to
antagonize H1-histamine receptor-mediated symptoms)
• H2- histamine receptor antagonist (to block activating H2-histamine receptors on mast cells;
to antagonize H2-histamine receptor-mediated symptoms)
• Cromolyn sodium (stabilising mast cells)
• Slow-release Vitamin C (increased degradation of histamine; inhibition of mast cell
degranulation; not more than 750 mg/day)
• If necessary, ketotifen to stabilise mast cells and to block activating H1-histamine receptors on
mast cells
Symptomatic treatment options (orally as
needed)
• Headache⇒ paracetamol; metamizole; flupirtine
• Diarrhea⇒ colestyramine; nystatin; montelukast; 5-HT3 receptor inhibitors (eg. ondansetron);
incremental doses (50-350 mg/day; extreme caution because of the possibility to induce mast
cell degranulation) of acetylsalicylic acid; (in steps test each drug for 5 days until improvement
of diarrhea)
• Colicky abdominal paindue to distinct meteorism ⇒ metamizole; butylscopolamine
• Nausea⇒ metoclopramide; dimenhydrinate; 5-HT3 receptor inhibitors; icatibant
• Respiratory symptoms(mainly increased production of viscous mucus and obstruction with
compulsive throat clearing) ⇒ montelukast; urgent: short-acting ß-sympathomimetic
• Gastric complaints⇒ proton pump inhibitors (de-escalating dose finding)
• Osteoporosis, osteolysis, bone pain⇒ biphosphonates ([51]; vitamin D plus calcium
application is second-line treatment in MCAD patients because of limited reported success and
an increased risk for developing kidney and ureter stones; [52])
• Non-cardiac chest pain⇒ when needed, additional dose of a H2-histamine receptor
antagonist; also, proton pump inhibitors for proven gastroesophageal reflux
• Tachycardia⇒ verapamil; AT1-receptor antagonists; ivabradin
• Neuropathic pain and paresthesia⇒ a-lipoic acid
• Interstitial cystitis⇒ pentosan, amphetamines
• Sleep-onset insomnia/sleep-maintenance insomnia⇒ triazolam/oxazepam
• Conjunctivitis⇒ exclusion of a secondary disease; otherwise preservative-free eye drops with
glucocorticoids for brief courses
• Hypercholesterolemia⇒ (does not depend on the composition of the diet) therapeutic trial
with HMG-CoA reductase inhibitors (frequently ineffective)
• Elevated prostaglandin levels, persistant flushing⇒ incremental doses of acetylsalicylic acid
(50-350 mg/day; extreme caution because of the possibility to induce mast cell degranulation)
All drugs should be tested for tolerance in a low single dose before therapeutic use, if their tolerance in the patient is not known from an earlier application.
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specific therapy responsible for a given improvement (or
deterioration). Ineffective or harmful agents should be
stopped promptly. If symptoms are resistant to therapy,
as a next therapeutic step toward reducing mast cell
activity and thereby decreasing mediator release, treat-
ment with prednisone, ciclosporine (cyclosporine A), low
dose methotrexate or azathioprine can be considered.
Recently, anti-IgE treatment with the humanized murine
monoclonal antibody omalizumab has alleviated high
intensity symptoms of MCAD [37]. Since treatment with
omalizumab has an acceptable risk-benefit profile, it
should be considered in cases of MCAD resistant to evi-
dence-based therapy. Recently, molecularly targeted ther-
apy by tyrosine kinase inhibitors such as imatinib
mesylate, dasatinib and midostaurin has been investi-
gated. As with all drugs used in therapy of MCAD, their
therapeutic success seems to be strongly dependent on
the individual patient. In formal studies in SM patients,
although the kinase inhibitors reduced mast cell burden
as reflected by histological normalization in bone marrow
and improved laboratory surrogate markers, at best only
partial improvement of mediator-related symptoms was
achieved [38-41]. However, in some case reports, imati-
nib and dasatinib have been significantly effective at
relieving symptoms. In spite of potential significant
adverse effects of these drugs, a therapeutic trial may be
justified in individual cases at an early stage. Given that
PI3K/AKT/mTOR is one of the downstream signalling
pathways upregulated by activated Kit, in theory mTOR
inhibitors (e.g., sirolimus, temsirolimus, everolimus) may
have utility in MCAD, but to date the one trial of this
notion (everolimus in SM) showed no significant clinical
activity [42].
A difficult situation is the occurrence of life-threaten-
ing anaphylaxis in patients with MCAD. If anaphylaxis
is provoked by a known allergen, especially hymenoptera
venom, immunotherapy should be considered with
recognition of potential risks [43-45]. In case of repeated
life-threatening anaphylactoid episodes, the self-adminis-
tration of epinephrine on demand has been recom-
mended as an appropriate approach.
In patients with high-grade variants of MCAD (pre-
sence of C-findings) and a progressive clini-cal course,
cytoreductive drugs are recommended and are pre-
scribed together with anti-mediator-type drugs [46,47].
Potential therapeutic options are interferon-a and 2-
chlorodeoxyadenosine (2-CdA, cladribine). Interferon-a
is frequently combined with prednisone and is com-
monly used as first-line cytoreductive therapy for
aggressive SM. It ameliorates SM-related organopathy in
a proportion of cases but is associated with considerable
adverse effects (e.g., flu-like symptoms, myelosuppres-
sion, depression, hypothyroidism), which may limit its
use in MCAD [48,49]. PEGylated interferon-a has been
shown to be as efficacious as, and less toxic than the
non-PEGylated form in some chronic myeloproliferative
diseases, but it has not been specifically studied in
MCAD. 2-Chlorodeoxyadenosine (2-CdA) is generally
reserved for last choice treatment of patients with
aggressive SM who are either refractory or intolerant to
interferon-a. Potential toxicities of 2-CdA include signif-
icant and potentially prolonged myelosuppression and
lymphopenia with increased risk of opportunistic infec-
tions. Patients who fail interferon-a and 2-CdA therapy
are candidates for experimental drugs. However, such
therapeutic maneuvers and their potential beneficial
effects have to be balanced against the long-term risk
and serious side effects of these therapies (often immu-
nosuppressive or/and mutagenic). Polychemotherapy
including intensive induction regimens of the kind used
in treating acute myeloid leukemia, as well as high-dose
therapy with stem cell rescue, represent investigational
approaches restricted to rare, selected patients. A variety
of other agents have been reported to have in-vitro
activity against at least some MCAD-associated muta-
tions [3] and may have a future role in the treatment of
this disease.
No tools yet exist to predict which specific therapeutic
regimen will be optimal for the individual MCAD
patient. However, especially in non-aggressive disease
(comprising the great majority of patients), at least par-
tial improvement is usually attainable with one regimen
or another, and thus the practitioner is obligated to per-
sist with therapeutic trials until no options remain.
Finally, although clinical trials in MCAD are rare, enrol-
ment in such must be a priority.
Conclusions
MCAD comprises disorders affecting functions in poten-
tially every organ system by abnormal release of media-
tors from and/or accumulation of genetically altered
mast cells. There is evidence that MCAD is a disorder
with considerable prevalence and thus should be consid-
ered routinely in the differential diagnosis of patients
with chronic multisystem polymorbidity of unknown
cause. In most cases of MCAD, diagnosis is possible by
relatively non-invasive investigation. Effective therapy
often consists simply of antihistamines and mast cell
membrane-stabilising compounds supplemented with
medications targeted at specific symptoms and
complications.
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